Many drugs have an optimum concentration range within which maximum beneficial. The concentrations above or below this range can be toxic or produces no benefit at all. New ideas on controlling the pharmacodynamics, Pharmacokinetics, Non-specific toxicity, biorecognition, immunogenicity and efficacy of drugs were generated. These new approaches called drug delivery system (DDS)1. These are based on interdisciplinary combination of polymer science, bioconjugate chemistry, molecular biology and pharmaceutics. To control the degradation and loss of drug, for the prevention of harmful sideeffects, increasing drug bioavailability accumulated in the required zone, various drug delivery system are currently under development.
Nanoparticles are at the cutting edge of the rapidly developing area of nanotechnology. The required potential for nanoparticles in cancer drug delivery is infinite2. Multifunctional nanoparticles play a significant role in cancer drug delivery3. The global market for advance drug delivery system was more than € 37.9 billion in 2000 and is estimated to grow and reach € 75B by 2005 (i.e. controlled release € 19.8 B, needle less injection € 0.8 B, injectable/implantable polymer systems € 5.4B, transdermal € 9.6, transnasal € 12.0B, pulmonary € 17.0B, Trans mucosal € 4.9 B, rectal € 0.9B, liposomal drug delivery € 2.5B, cell/gene therapy € 3.8B, miscellaneous € 1.6B,). The review provides recent researches in novel drug delivery.
Drug delivery, nanoparticles, SWCNT, metabolism
